Abstract:Background: ABL tyrosine kinase inhibitors (TKI) have dramatically improved chronic myeloid leukemia (CML) survival. Due to resistance to the first ABL-TKI imatinib (Ima), most patients are treated with newer agents, including ponatinib (Pon). Although Pon improves cancer remission, the survival benefit is mitigated by a 4-fold increase in arterial thrombosis. The mechanism of Pon-induced arterial thrombosis and the safety of Asciminib (Asc), a newly approved alternative, are not known. CML patients are older and have notably elevated serum TNFa levels. Hypothesis: Since arterial thrombotic events occur when inflamed vascular plaques rupture, we tested the hypothesis that Pon enhances endothelial cell (EC) response to TNFa, promoting EC inflammation and leukocyte trafficking. Methods and Results: In vitro: Human umbilical vein ECs (HUVECs) were treated with Pon, Ima, or Asc at concentrations observed in humans. Adhesion molecules that mediate leukocyte rolling (E- and P-selectin) and adhesion (ICAM1, VCAM1), and TNF receptors (TNFR) 1 and 2 were quantified at 24 hours by qPCR, flow cytometry (FC), and immunoblot. Pon increased TNFR2, P-selectin, VCAM, and ICAM by FC, qPCR, and immunoblot while Ima and Asc had no impact. In primary human coronary artery ECs Pon, but not Asc nor Ima, similarly increased VCAM and P-selectin mRNA. Pretreatment of HUVECs with a nonspecific TNFR inhibitor prevented Pon induction of ICAM1 and P-selectin mRNA. In vivo: Mice were treated with ABL TKIs by oral gavage to achieve drug plasma levels consistent with those in CML patients. After three days, leukocyte trafficking was quantified by intravital microscopy (IVM) in mouse mesenteric vessels. Pon, but not Asc, increased the number of rolling and adherent leukocytes, and increased serum TNFa by ELISA. Treatment with a TNFR inhibitor blocked Pon induced leukocyte trafficking by IVM. Conclusion: Pon, but not Ima nor Asc, induces expression of TNF receptors and adhesion molecules in human ECs in vitro and promotes leukocyte trafficking in vivo. Since inflamed plaques lead to acute arterial thrombosis, this mechanism could contribute to the high risk of arterial thrombosis in Pon-treated cancer patients. If so, Asc may be a safer choice as it does not induce EC inflammation.

Ponatinib: An update on its drug targets, therapeutic potential and safety

Ponatinib‐review of historical development, current status, and future research

Ponatinib: A Review of the History of Medicinal Chemistry behind Its Development

Research Progress of Multi-targeted Tyrosine Kinase Inhibitor-Ponatinib

Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies

How Does the Novel T315L Mutation of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Confer Resistance to Ponatinib: a Comparative Molecular Dynamics Simulation Study

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management

Abstract 121: Ponatinib Promotes Endothelial Cell Inflammation And Leukocyte Trafficking Via Tumor Necrosis Factor Signaling: A Potential Mechanism Of Vascular Toxicity

Multi-targeted Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer: an Era of Individualized Therapy.

Anlotinib: A Novel Molecular-Targeted Drug for Tumours

Comparative Efficacy and Safety of Different Doses of Ponatinib Versus Other Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia: a Systematic Review and Network Meta-Analysis.

Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase

Anlotinib As a Molecular Targeted Therapy for Tumors (Review)

Research Status, Synthesis and Clinical Application of Recently Marketed and Clinical BCR-ABL Inhibitors

Anlotinib as a molecular targeted therapy for tumors

Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells.

Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia

Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation

[Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with BCR-ABL T315I Mutation--Review].

A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia